story of the week
Alpelisib + Fulvestrant in PIK3CA-Altered and PIK3CA Wild-Type ER+ Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial
JAMA Oncol 2018 Dec 13;[EPub Ahead of Print], D Juric, F Janku, J Rodón, HA Burris, IA Mayer, M Schuler, R Seggewiss-Bernhardt, M Gil-Martin, MR Middleton, J Baselga, D Bootle, D Demanse, L Blumenstein, K Schumacher, A Huang, C Quadt, HS RugoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.